

REMARKS

In response to Examiner Roark's suggestions, claims 36 and 39 have been amended. This Supplemental Preliminary Amendment is submitted in compliance with 37 CFR 1.121. Claim 36 now reads, "A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising: . . .". Claim 39 now reads "A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising: . . .". Applicants expressly state that these claims are **not** being amended for reason related to patentability, and are in fact fully supported by the specification as filed.

By this Supplemental Preliminary Amendment, claims 11, 36-39, 41, and 44 were amended to place the claims in better form for examination and have not been made for reasons relating to patentability. Applicants respectfully request acceptance and entry of this Supplemental Preliminary Amendment.

Restriction Requirement

In the Restriction Requirement, the Examiner requested Applicants to elect one of the following inventions:

Group I (claim 1) drawn to a polypeptide comprising SEQ ID NO:1 and variants thereof, classified in Class 435, subclass 183.

Group II (claims 11, 31-32, 34, 36-43) drawn to antibodies to the polypeptide of SEQ ID NO:1, compositions thereof, and methods of making the antibodies, classified in Class 530, subclass 387.1; Class 424, subclass 130.1; and Class 435, subclass 326.

Group III (claims 30 and 44) drawn to a method/diagnostic test for a condition associated with expression of the polypeptide of SEQ ID NO:1, each comprising detecting the polypeptide in a biological sample; classified in Class 436, subclass 63 and Class 435, subclass 7.1.

Group IV (claims 33 and 35) drawn to a method of diagnosing a condition associated with expression of the polypeptide of SEQ ID NO:1 by administering an antibody to the polypeptide to a subject, classified in Class 424, subclass 130.1 and Class 435, subclass 7.1.

Group V (claim 45) drawn to method for using an antibody to purify the polypeptide of SEQ ID NO:1 from a sample; classified in Class 530, subclass 413.

Docket N .. PF-0334-2 DIV

Applicants hereby elect, with traverse, to prosecute Group II, which includes and is drawn to claims 11, 31-32, 34, and 36-43 drawn to antibodies which specifically bind to polypeptides SEQ ID NO:1, compositions comprising the antibodies, and a method of making antibodies, with traverse.

Claims directed to methods of using the claimed antibodies for diagnosing a condition or disease (i.e., claims 30, 33, and 35), for detecting a polypeptide of SEQ ID NO:1 (i.e., claim 44), and for purifying a polypeptide of SEQ ID NO:1 (i.e., claim 45), could and should be examined together with the product claims from which they depend, per the Commissioner's Notice in the Official Gazette of March 26, 1996, entitled "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)" which sets forth the rules, upon allowance of one of the product claims, for rejoinder of process claims covering the same scope of products. Applicants presume these method claims will be rejoined, upon determining allowability of the product claims from which they depend.

Applicants reserve the right to prosecute non-elected subject matter in subsequent divisional applications.

If the Examiner contemplates other action, or if a telephone conference would expedite allowance of the claims, Applicants invite the Examiner to contact the undersigned at (650) 621-8555.

Applicants believe that no fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 09-0108.

Docket No.: PF-0334-2 DIV

Respectfully submitted,
INCYTE GENOMICS, INC.

Date: 07 October 2002

Shirley A. Recipon
Shirley A. Recipon
Reg. No. 47,016
Direct Dial Telephone: (650) 621-8555

Date: 07 October 2002

Richard C. Ekstrom
Richard C. Ekstrom
Reg. No. 37,027
Direct Dial Telephone: (650) 843-7352

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

Docket No.: PF-0334-2 DIV

**VERSION WITH MARKINGS TO SHOW CHANGES MADE
IN THE SPECIFICATION:**

The first paragraph of page 1 has been amended as follows:

This application is a divisional [of] application of U.S. application serial number 09/258,643 filed on February 26, 1999, now U.S. Patent No. 6,277,373, which is a divisional [of] application of U.S. application serial number 08/884,681 filed on June 27, 1997, now U.S. [patent number] Patent No. 5,955,338, the contents all of which are hereby incorporated by reference.

IN THE CLAIMS:

Claim 1 has been canceled.

Claims 11, 36-39, 41, and 44 have been amended as follows:

11. (Once Amended) An isolated antibody which specifically binds to a polypeptide [of claim 1] selected from the group consisting of:

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1.
- b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 and having phosphatidylinositol 4,5-bisphosphate 5-phosphatase activity.
- c) an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1.

36. (Once Amended) A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence of SEQ ID NO:1[,] or an immunogenic fragment thereof, under conditions to elicit an antibody response;
- b) isolating antibodies from said animal; and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.

Docket N .: PF-0334-2 DIV

37. (Once Amended) [An] A polyclonal antibody produced by a method of claim 36.

38. (Once Amended) A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. (Once Amended) A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence of SEQ ID NO:1[,] or an immunogenic fragment thereof, under conditions to elicit an antibody response;
- b) isolating antibody producing cells from the animal;
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
- d) culturing the hybridoma cells; and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.

41. (Once Amended) A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.

44. (Once Amended) A method for detecting a polypeptide having an amino acid sequence of SEQ ID NO:1 in a sample, the method comprising [the steps of]:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence of SEQ ID NO:1 in the sample.

1	M D V L S P L S	- - - - -	638789
1	A R -	- - - - -	91399105
1	V T V P E P G A A E S R A P C G D S S G G C V R S A G A S M D Q S V A I Q E T L	- - - - -	91019103
1	M E P P L P V G A Q P L A	- - - - -	g1420920
9	*	- - - - -	638789
3	- - - - -	- - - - -	91399105
41	A E G E Y C C V I A V Q G V L C E G D S R Q S R L L G L V R Y R L E H G G Q E H A	- - - - -	g1019103
23	- - - - -	- - - - -	g1420920
9	- - - - -	- - - - -	638789
3	- - - - -	- - - - -	91399105
81	L F L Y T H R R M A I T G D D V S L D O I V P V S R D F T L E E V S P D G E L Y	- - - - -	g1019103
41	L I I Q L H E K - - - - -	E Q H V Q D I I P I N S H F R C V Q E A E E T L L I	g1420920
9	- - - - -	- - - - -	638789
3	- - - - -	- - - - -	91399105
121	I L G S D V T V Q L D T A E L S L V F Q L P F G S Q T R M F L H E V A R A C P G	- - - - -	g1019103
75	D I A S N S G C K I R V Q G D W I - - - - -	R E R R F E I P D E E H C L K	g1420920
9	- - - - -	- - - - -	638789
3	- - - - -	- - - - -	91399105
161	F D S A T R D P E F L W L S R Y R C A E L E E M P T P R G C N S A L V T W P G	- - - - -	g1019103
107	F L S A V L A A Q K - - - - -	A Q S Q L L V P E Q K D S S S - - - - -	g1420920
9	- - - - -	- - - - -	638789
3	- - - - -	- - - - -	91399105
201	Y A T I G G G - - - S N F D G L - - - R P N G K G V P M D Q S S R G Q D K P E S	- - - - -	g1019103
133	Y Q K L D T K D K P S V F S G L L G F E D N F S S M N L D K K I N S Q N Q P T G	- - - - -	g1420920

FIGURE 2A

FIGURE 2B

107	DHDLLIWFGDMNFRRIEDFGLHFVRESIKNRCKYGGGLWEKDQ	638789
3	- - - - - GHLHEVKFAI DSDQHQ LWEKDDQ	91399105
467	NHDVILWLGDLNRYRILEDVEKVKKLIEEKDFQMLLYAYDQ	91019103
413	KHEVVIWLGDLNYRLCMPPDANEVKSLINKKDQLQRILLKEFDQ	91420920
147	LSIAKKHDPILLREFOEGRLLFPPTYKFDRNSNDYDTSEKK	638789
25	LNMMAKNTWHLKGFQEGP NFA PTFKF VGTN KYDTSAKK	91399105
507	LKIQVAAKTVFEGFTEGELTFOPTYKYSDDWDTSEKCKC	91019103
453	LNIQRTQKKAFAVDENEGEEKFIPPTYKYSKTDRDWSSGKCKC	91420920
187	RKPAWTDRILWRLKROPCAGPDTEPLIPPAASHFESLRLRGYSS	638789
65	RKPAWTDRILWRLKVK-A PGGGP SPSGRKSHRLQVTQHSSYRS	91399105
547	RAPAWCDRILWKGK- - - - - - - - - - - - - - - -	91019103
493	RVPAWCDRILWRGK- - - - - - - - - - - - - - - -	91420920
227	HMTYGLISDHKPVSGTFDLEILKPLVSAPELLVLMPEDLHWTV-	638789
104	HMEYTVSDHKPVAAQFLQFAFRDDMPLLVR LEVADEWVVR-	91399105
570	HMALKTSDHKPVSSVFDIGVRVVNDELYRKTLIEIVRSLD	91019103
516	HMELKTSDHKPVSALLEHIGVWKVVVDERRYRKVFEDSVRIMD	91420920
266	- - ENDMMVSYSSSTS-DFPSSPWDMWIGLYKVGLRDWNDD--	638789
143	- - PEQAVVYR RMET-VFAR S W D W G F R H C K D ---	91399105
610	KMENANIPSVSLSKREFCFQNVKYMQ L K V E S F T I -HNCGQV	91019103
556	RMENDFLPSLELSRRFFVFEVVKFRQLQ K G K F Q 1 S N NGQV	91420920
300	- - - YVS -	638789
177	- - - YVA -	638789
649	PCHFESFINKPDEESYCKPWLRAEPFEGYLEPNETV D I S L D	91019103
596	PCHFSSFIPLNDSQYCKPWLRAEPFEGYLEPNETV D I S L D	91420920

FIGURE 2C

Title: N-[**██████████**] PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE
Serial No.: 09/892,287

317	L N O V Y I D I S N I P T T E D	[E F] 638789
192	T Y Q V T F S E E S L P K G H G	- - - - - D F g1399105
689	D F V N K T T A T K L N S S G E D	- - - - - D F g1019103
636	V Y V S K D S V T I L N S G E D	- - - - - D F g1420920
335	L L C Y Y S N S L R S V U G I S R P F	[Q I E] - - - - -
210	I J G Y Y S H N H S I L I G I T E P F	[Q I S L P S] - - - - -
729	L P S C F G S P I I H T L C Y M R E	P I L D P L E T I S E L - - - - -
676	L P S C F G T S I E A L C R M K R P I R E V E	V T K L I D L E E D S F L E K E K g1420920
357	- - - - - S E G E D D S T L E - - - - -	638789
248	S - - - - - T L M P V W T G D D G S Q L D S P M E I P K E L W M M V D Y L Y R N A V Q Q E D	- - - - - R P S S R G A S S R S P S P G K S K R H R S P G g1399105
759	T L M P V W T G D D G S Q L D S P M E I P K E L W M M V D Y L Y R N A V Q Q E D	- - - - - R P S S R G A S S R S P S P G K S K R H R S P G g1019103
716	S L L Q M V P L D E G A S - E R P L Q V P K E I W L V D H L F K Y A C H Q Q E D	- - - - - R P S S R G A S S R S P S P G K S K R H R S P G g1420920
357	- - - - - L A R F P G L A - - - - -	638789
282	L A R F P G L A - - - - -	- - - - - R P S S R G A S S R S P S P G K S K R H R S P G g1399105
799	L F Q Q P G L R S E F E H I R D C L D T G M I O N L S A S N H S V A E A L L F g1019103	- - - - - R P S S R G A S S R S P S P G K S K R H R S P G g1420920
755	L F Q T P G M Q Q E E L Q Q I I D C L D T S I P E T I P G S N H S V A E A L L F g1420920	- - - - - R P S S R G A S S R S P S P G K S K R H R S P G g1399105
357	- - - - - S N G S S S R G S S E G P S G L P G P W A F P P A V P R S - - -	638789
313	R V A - P D R S S N G S S S R G S S E G P S G L P G P W A F P P A V P R S - - -	- - - - - R P S S R G A S S R S P S P G K S K R H R S P G g1019103
839	L E S L P P E P V I C Y S T Y H N C L E C S G N Y T A S K Q V I S T L P I F H K N g1420920	- - - - - R P S S R G A S S R S P S P G K S K R H R S P G g1420920
795	L E A L P E P V I C Y E L Y Q R C L D S A Y D P R I C R Q V I S Q L P R C H R N g1420920	- - - - - R P S S R G A S S R S P S P G K S K R H R S P G g1399105
349	- - - - - L G L L P A L - R L E T V D P G G G S W G P D R E A L - - -	[P G] 638789
879	V F H Y L M A F L R E L L K F S E Y N S V N A N M I A T L F T S L L R P P P N g1019103	- - - - - A P N 91399105
835	V F R Y L M A F L R E L L K F S E Y N S V N A N M I A T L F T S L L R P P P N g1420920	- - - - - A P N 91019103

FIGURE 2D